Brokerages expect that Ra Pharmaceuticals Inc (NASDAQ:RARX) will post earnings of ($0.57) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ra Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.64) and the highest estimate coming in at ($0.47). Ra Pharmaceuticals posted earnings of ($0.47) per share during the same quarter last year, which would indicate a negative year over year growth rate of 21.3%. The firm is expected to issue its next earnings report on Thursday, March 5th.
On average, analysts expect that Ra Pharmaceuticals will report full year earnings of ($2.05) per share for the current fiscal year, with EPS estimates ranging from ($2.16) to ($1.81). For the next year, analysts anticipate that the firm will post earnings of ($2.66) per share, with EPS estimates ranging from ($3.04) to ($2.33). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Ra Pharmaceuticals.
Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.05). The firm had revenue of $3.00 million during the quarter.
Several equities research analysts recently commented on RARX shares. Svb Leerink cut Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and increased their price objective for the company from $38.00 to $48.00 in a research report on Friday, October 11th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $48.00 price objective on shares of Ra Pharmaceuticals in a research report on Friday, October 11th. Leerink Swann cut Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $48.00 price objective on the stock. in a research report on Friday, October 11th. SunTrust Banks cut Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 14th. Finally, Robert W. Baird cut Ra Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $48.00 price objective on the stock. in a research report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating and thirteen have issued a hold rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $45.36.
In other Ra Pharmaceuticals news, insider Ramin Farzaneh-Far sold 10,595 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.26, for a total value of $267,629.70. Following the transaction, the insider now directly owns 8,521 shares of the company’s stock, valued at $215,240.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alonso Ricardo sold 2,285 shares of the firm’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $46.70, for a total value of $106,709.50. Following the completion of the transaction, the insider now directly owns 6,858 shares in the company, valued at $320,268.60. The disclosure for this sale can be found here. Insiders sold 34,070 shares of company stock worth $1,365,501 over the last three months. Insiders own 4.30% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Prudential Financial Inc. boosted its position in Ra Pharmaceuticals by 0.5% in the second quarter. Prudential Financial Inc. now owns 120,890 shares of the company’s stock worth $3,635,000 after purchasing an additional 640 shares during the last quarter. Virginia Retirement Systems ET AL boosted its position in Ra Pharmaceuticals by 12.9% in the second quarter. Virginia Retirement Systems ET AL now owns 10,500 shares of the company’s stock worth $316,000 after purchasing an additional 1,200 shares during the last quarter. Meeder Asset Management Inc. boosted its position in Ra Pharmaceuticals by 26.2% in the third quarter. Meeder Asset Management Inc. now owns 6,209 shares of the company’s stock worth $147,000 after purchasing an additional 1,290 shares during the last quarter. Swiss National Bank boosted its position in Ra Pharmaceuticals by 3.6% in the second quarter. Swiss National Bank now owns 49,300 shares of the company’s stock worth $1,482,000 after purchasing an additional 1,700 shares during the last quarter. Finally, Bank of Montreal Can raised its stake in shares of Ra Pharmaceuticals by 218.0% in the second quarter. Bank of Montreal Can now owns 3,832 shares of the company’s stock worth $115,000 after buying an additional 2,627 shares during the period.
Shares of Ra Pharmaceuticals stock traded down $0.15 during trading on Friday, hitting $47.20. 246,022 shares of the company’s stock traded hands, compared to its average volume of 534,988. The company has a debt-to-equity ratio of 0.01, a current ratio of 25.73 and a quick ratio of 25.73. Ra Pharmaceuticals has a 1 year low of $15.23 and a 1 year high of $47.48. The stock has a market capitalization of $2.23 billion, a P/E ratio of -22.91 and a beta of 1.49. The business has a 50-day simple moving average of $46.83 and a 200-day simple moving average of $33.74.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Featured Article: What is Cost of Goods Sold (COGS)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.